{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:55:23Z","timestamp":1760122523272},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"EU\u2018s 7th Framework Programme","award":["FP HEALTH 2013 \u2013 602144"],"award-info":[{"award-number":["FP HEALTH 2013 \u2013 602144"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0402-6","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T09:34:23Z","timestamp":1455960863000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions"],"prefix":"10.1186","volume":"11","author":[{"given":"Steffen","family":"Unkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"R\u00f6ver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Stallard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Benda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,20]]},"reference":[{"key":"402_CR1","first-page":"15","volume":"L 18","author":"Orphan Medicinal Product Regulation","year":"2000","unstructured":"Orphan Medicinal Product Regulation. Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J. 2000;L 18:15.","journal-title":"Off J"},{"key":"402_CR2","unstructured":"European Commission [Internet]. Brussels: Directorate-General for Health and Food Safety [cited 2015 Mar 20]. Available from: http:\/\/ec.europa.eu\/health\/rare_diseases\/policy\/ ."},{"key":"402_CR3","doi-asserted-by":"crossref","unstructured":"Editorial. Rare neurological diseases: a united approach is needed. Lancet Neurol. 2011;10(2):109.","DOI":"10.1016\/S1474-4422(11)70001-1"},{"issue":"3","key":"402_CR4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jpeds.2013.04.028","volume":"163","author":"K Haren Van","year":"2013","unstructured":"Van Haren K, Waubant E. Therapeutic advances in pediatric multiple sclerosis. J Pediatr. 2013;163(3):631\u20137.","journal-title":"J Pediatr"},{"key":"402_CR5","unstructured":"Orphanet [Internet]. Paris [updated 2015 July]. [cited 2015 Aug 7]. Available from: http:\/\/www.orpha.net ."},{"key":"402_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/s-0033-1359308","volume":"44","author":"B Kornek","year":"2013","unstructured":"Kornek B. Treatment of pediatric multiple sclerosis. Neuropediatrics. 2013;44:309\u201313.","journal-title":"Neuropediatrics"},{"key":"402_CR7","unstructured":"National Multiple Sclerosis Society [Internet]. New York City [cited 2015 Apr 21]. Available from: http:\/\/www.nationalmssociety.org\/ ."},{"key":"402_CR8","volume-title":"Prevalence of rare diseases: bibliographic data","author":"Orphanet Report Series","year":"2014","unstructured":"Orphanet Report Series. Prevalence of rare diseases: bibliographic data, vol. 1. 2014."},{"key":"402_CR9","unstructured":"Creutzfeldt-Jakob disease fact sheet. National Institute of Neurological Disorders and Stroke. Bethesda, MD [cited 2015 Apr 21]. Available from: http:\/\/www.ninds.nih.gov\/disorders\/cjd\/detail_cjd.htm ."},{"key":"402_CR10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/clpt.2013.218","volume":"95","author":"AS Kesselheim","year":"2014","unstructured":"Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95:265\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"402_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-90-481-9485-8_2","volume":"686","author":"MP Paz De la","year":"2010","unstructured":"De la Paz MP, Villaverde-Hueso A, Alonso V, J\u00e1nos S, Zurriaga O, Poll\u00e1n M, et al. Rare diseases epidemiology research. Adv Exp Med Biol. 2010;686:17\u201339.","journal-title":"Adv Exp Med Biol"},{"key":"402_CR12","unstructured":"European Medicines Agency (EMA). Guideline on clinical trials in small populations. London:European Medicines Agency; 2006."},{"issue":"6","key":"402_CR13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.2010.31.1423","volume":"29","author":"EL Korn","year":"2011","unstructured":"Korn EL, Freidlin B. Outcome-adaptive randomization: Is it useful? J Clin Oncol. 2011;29(6):771\u20136.","journal-title":"J Clin Oncol"},{"issue":"6795","key":"402_CR14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bmj.303.6795.173","volume":"303","author":"T Johannessen","year":"1991","unstructured":"Johannessen T. Controlled trials in single subjects. 1. Value in clinical medicine. BMJ. 1991;303(6795):173\u20134.","journal-title":"BMJ"},{"key":"402_CR15","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: Wiley; 2004."},{"key":"402_CR16","unstructured":"Food and Drug Administration (FDA). Rare diseases: common issues in drug development. Draft guidance for industry. Silver Spring, Maryland:Food and Drug Administration; 2015."},{"key":"402_CR17","doi-asserted-by":"crossref","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O\u2019Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.","journal-title":"BMJ"},{"issue":"178","key":"402_CR18","first-page":"178sr3","volume":"5","author":"EL Korn","year":"2013","unstructured":"Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med. 2013;5(178):178sr3.","journal-title":"Sci Transl Med"},{"key":"402_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1172-8-48","volume":"8","author":"C Cornu","year":"2013","unstructured":"Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48.","journal-title":"Orphanet J Rare Dis"},{"key":"402_CR20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62:1006\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"402_CR21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1378\/chest.09-2625","volume":"137","author":"B Wieseler","year":"2010","unstructured":"Wieseler B, McGauran N. Reporting a systematic review. Chest. 2010;137(5):1240\u20136.","journal-title":"Chest"},{"key":"402_CR22","unstructured":"Higgins JPT, Altman DG, Sterne, JAC (editors). Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http:\/\/www.cochrane-handbook.org ."},{"key":"402_CR23","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration","author":"BC Reeves","year":"2011","unstructured":"Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http:\/\/www.cochrane-handbook.org."},{"key":"402_CR24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/01.wnl.0000342200.58823.6a","volume":"72","author":"RA Gross","year":"2009","unstructured":"Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology. 2009;72:8\u201310.","journal-title":"Neurology"},{"key":"402_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"402_CR26","first-page":"116","volume":"Spec No 3","author":"OV Bykova","year":"2006","unstructured":"Bykova OV, Studenikin VM, Kuzenkova LM, Maslova OI, Bo\u012dko AN. Effective treatment of multiple sclerosis with rebif-22 mcg in children and adolescences: results of a long-term study. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Spec No 3:116\u201321.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"9","key":"402_CR27","first-page":"29","volume":"106","author":"OV Bykova","year":"2006","unstructured":"Bykova OV, Kuzenkova LM, Maslova OI. The use of beta-interferon-1b in children and adolescents with multiple sclerosis. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(9):29\u201333.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"4","key":"402_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2006-924723","volume":"37","author":"H Pakdaman","year":"2006","unstructured":"Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics. 2006;37(4):257\u201360.","journal-title":"Neuropediatrics"},{"issue":"3","key":"402_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10072-009-0083-1","volume":"30","author":"A Ghezzi","year":"2009","unstructured":"Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009;30(3):193\u20139.","journal-title":"Neurol Sci"},{"issue":"3","key":"402_CR30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10072-007-0804-2","volume":"28","author":"A Ghezzi","year":"2007","unstructured":"Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci. 2007;28(3):127\u201332.","journal-title":"Neurol Sci"},{"issue":"Suppl 4","key":"402_CR31","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1007\/s10072-005-0512-8","volume":"26","author":"A Ghezzi","year":"2005","unstructured":"Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci. 2005;26 Suppl 4:S183\u20136.","journal-title":"Neurol Sci"},{"issue":"4","key":"402_CR32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1191\/1352458505ms1206oa","volume":"11","author":"A Ghezzi","year":"2005","unstructured":"Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4):420\u20134.","journal-title":"Mult Scler"},{"issue":"6700","key":"402_CR33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/bmj.299.6700.663","volume":"299","author":"SJ Day","year":"1989","unstructured":"Day SJ, Graham DF. Sample size and power for comparing two or more treatment groups in clinical trials. BMJ. 1989;299(6700):663\u20135.","journal-title":"BMJ"},{"issue":"7","key":"402_CR34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0883073813488828","volume":"28","author":"SN Tenembaum","year":"2013","unstructured":"Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28(7):849\u201356.","journal-title":"J Child Neurol"},{"issue":"4","key":"402_CR35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1212\/01.wnl.0000198257.52512.1a","volume":"66","author":"B Banwell","year":"2006","unstructured":"Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472\u20136.","journal-title":"Neurology"},{"issue":"5","key":"402_CR36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/01.WNL.0000153570.33845.6A","volume":"64","author":"D Pohl","year":"2005","unstructured":"Pohl D, Rostasy K, G\u00e4rtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888\u201390.","journal-title":"Neurology"},{"issue":"3","key":"402_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejpn.2007.08.001","volume":"12","author":"Y Mikaeloff","year":"2008","unstructured":"Mikaeloff Y, Caridade G, Tardieu M, Suissa S, KIDSEP study group of the French Neuropediatric Society. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol. 2008;12(3):205\u20139.","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"402_CR38","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","volume":"62","author":"M Otto","year":"2004","unstructured":"Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double blind study. Neurology. 2004;62(5):714\u20138.","journal-title":"Neurology"},{"issue":"23","key":"402_CR39","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","volume":"81","author":"MD Geschwind","year":"2013","unstructured":"Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015\u201323.","journal-title":"Neurology"},{"issue":"4","key":"402_CR40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","volume":"8","author":"J Collinge","year":"2009","unstructured":"Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334\u201344.","journal-title":"Lancet Neurol"},{"issue":"2","key":"402_CR41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt\u2013Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150\u20138.","journal-title":"Lancet Neurol"},{"key":"402_CR42","doi-asserted-by":"crossref","DOI":"10.1201\/b18041","volume-title":"Modelling survival data in medical research","author":"D Collett","year":"2015","unstructured":"Collett D. Modelling survival data in medical research. 3rd ed. Boca Raton: Chapman & Hall\/CRC; 2015.","edition":"3"},{"issue":"suppl","key":"402_CR43","doi-asserted-by":"crossref","first-page":"T149","DOI":"10.1016\/j.jalz.2008.05.373","volume":"4","author":"F Tagliavini","year":"2008","unstructured":"Tagliavini F. Prion therapy: tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease. Alzheimers Dement. 2008;4(suppl):T149\u201350.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"402_CR44","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","volume":"63","author":"S Ha\u00efk","year":"2004","unstructured":"Ha\u00efk S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Laupr\u00eatre N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63(12):2413\u20135.","journal-title":"Neurology"},{"issue":"1","key":"402_CR45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458511430704","volume":"18","author":"T Chitnis","year":"2012","unstructured":"Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18(1):116\u201327.","journal-title":"Mult Scler"},{"key":"402_CR46","doi-asserted-by":"crossref","first-page":"f6409","DOI":"10.1136\/bmj.f6409","volume":"347","author":"N Freemantle","year":"2013","unstructured":"Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409.","journal-title":"BMJ"},{"key":"402_CR47","unstructured":"Evans CH Jr, Ildstad ST, editors. Small Clinical Trials: Issues and Challenges. Washington, D. C.:National Academies Press; 2001."},{"issue":"3","key":"402_CR48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1756285612437360","volume":"5","author":"SN Tenembaum","year":"2012","unstructured":"Tenembaum SN. Ethical challenges in paediatric clinical trials in multiple sclerosis. Ther Adv Neurol Disord. 2012;5(3):139\u201346.","journal-title":"Ther Adv Neurol Disord"},{"key":"402_CR49","unstructured":"EMA [Internet]. London. [cited 2015 July 21]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500143702.pdf ."},{"key":"402_CR50","doi-asserted-by":"crossref","DOI":"10.1002\/0470033312","volume-title":"Uncertain judgements: Eliciting Experts\u2019 Probabilities","author":"A O\u2019Hagan","year":"2006","unstructured":"O\u2019Hagan A, Buck CE, Daneshkhah A, et al. Uncertain judgements: Eliciting Experts\u2019 Probabilities. Chichester: Wiley; 2006."},{"issue":"24","key":"402_CR51","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1002\/sim.6225","volume":"33","author":"LV Hampson","year":"2014","unstructured":"Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med. 2014;33(24):4186\u2013201.","journal-title":"Stat Med"},{"issue":"4","key":"402_CR52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1191\/1740774505cn102oa","volume":"2","author":"SN Goodman","year":"2005","unstructured":"Goodman SN, Sladky JT. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barr\u00e9 syndrome. Clin Trials. 2005;2(4):305\u201310.","journal-title":"Clin Trials"},{"key":"402_CR53","unstructured":"European Medicines Agency (EMA). Concept paper on extrapolation of efficacy and safety in medicine development. London:European Medicines Agency; 2012."},{"key":"402_CR54","unstructured":"Food and Drug Administration (FDA). Leveraging existing clinical data for extrapolation to pediatric uses of medical devices. Draft guidance. Silver Spring, Maryland:Food and Drug Administration; 2015."},{"key":"402_CR55","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet"},{"key":"402_CR56","doi-asserted-by":"crossref","first-page":"436046","DOI":"10.5402\/2012\/436046","volume":"2012","author":"O Gross","year":"2012","unstructured":"Gross O, Friede T, Hilgers R, G\u00f6rlitz A, Gav\u00e9nis K, Ahmed R, et al. Safety and efficacy of the ace-inhibitor ramipril in alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT alport trial in pediatric patients. ISRN Pediatr. 2012;2012:436046.","journal-title":"ISRN Pediatr"},{"key":"402_CR57","volume-title":"Doxycycline in early Creutzfeldt-Jakob disease \u2013 double-blinded randomized phase II and observational study","author":"D Varges","year":"2015","unstructured":"Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Krasnianski A, et al. Doxycycline in early Creutzfeldt-Jakob disease \u2013 double-blinded randomized phase II and observational study. 2015. Submitted for publication."},{"key":"402_CR58","doi-asserted-by":"crossref","DOI":"10.1002\/9781119942986","volume-title":"Evidence synthesis for decision making in healthcare","author":"NJ Welton","year":"2012","unstructured":"Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Chichester: Wiley; 2012."},{"key":"402_CR59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774510373497","volume":"7","author":"B Neuenschwander","year":"2010","unstructured":"Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials. 2010;7:5\u201318.","journal-title":"Clin Trials"},{"issue":"8","key":"402_CR60","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1352458512471878","volume":"19","author":"A Ghezzi","year":"2013","unstructured":"Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19(8):1106\u201312.","journal-title":"Mult Scler"},{"issue":"4","key":"402_CR61","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","volume":"70","author":"B Kornek","year":"2013","unstructured":"Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70(4):469\u201375.","journal-title":"JAMA Neurol"},{"issue":"3","key":"402_CR62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/01.wnl.0000231137.24467.aa","volume":"67","author":"SN Tenembaum","year":"2006","unstructured":"Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511\u20133.","journal-title":"Neurology"},{"key":"402_CR63","unstructured":"Fincke F. Doxycyclin bei der sporadischen Creutzfeldt-Jakob-Krankheit. PhD thesis. Goettingen:University Medical Center Goettingen; 2010."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0402-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T21:38:26Z","timestamp":1600205906000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/11\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,20]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0402-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,20]]},"article-number":"16"}}